Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

StreetInsider04-11

– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426261098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-11 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426261098","market":"us","top_or_hot":-1,"title":"Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance","media":"StreetInsider","content":"<div>\n<p>– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting –\nSAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23056032\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=23056032><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting –\nSAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23056032\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVTA","symbol_name":"Invitae Corporation","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=23056032","article_id":"2426261098","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426261098","pubTimestamp":1712849400,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting –。SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae , a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting  held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance  in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.\"We're excited to demonstrate that machine learning algorithms are able to provide more accurate and equitable results for breast cancer patients with VUS,\" said Dr. Ed Esplin M.D., Ph.D., FACMG, Clinical Geneticist at Invitae and co-author of the study. \"These definitive results can help improve outcomes for these patients and is just one example of ","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVTA":"Invitae Corporation","BK4139":"生物科技","BK4196":"保健护理服务"},"translate_title":"Invitae公布了针对具有不确定重要性变异的乳腺癌患者的新研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVTA":1},"content_text":"– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting –\nSAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.\n\n\n\n\n\nNew findings show machine learning models can help reduce the burden on clinicians and patients in the process of resolving uncertain genetic test results for hereditary breast cancer, particularly for underrepresented populations. \nDue to limited evidence, classifying uncertain variants can be challenging. Individuals from certain racial, ethnic and ancestral (REA) populations are often underrepresented in large genomic databases and medical literature, leading to less definitive results, resulting in VUS which are at the center of healthcare disparities. To generate more definitive genetic testing results for these groups, the study sought to develop gene-specific machine learning models and evaluate their usefulness in genetic testing for patients with breast cancer.\nAfter validating gene-specific machine learning algorithms, the impact on variant classification was analyzed in patients with breast cancer who underwent hereditary cancer genetic testing from January 2022 - May 2023. The study found that among breast cancer patients who had at least one variant with machine learning evidence applied, more than 15% resulted in a definitive (non-VUS) variant classification. However, when stratifying the analysis by REA populations, a higher percentage of Black (22%), Asian (28%), and Hispanic (19%) individuals with breast cancer had a definitive classification that was determined by machine learning evidence compared to White (12%) individuals, suggesting that machine learning evidence is particularly useful for patients from historically underrepresented populations with breast cancer who undergo hereditary cancer testing. By reclassifying these VUS into definitive results, laboratories can help clinicians better manage the care of their patients and help reduce gaps in healthcare disparities across racial, ethnic, and socio-economic groups.\n\"We're excited to demonstrate that machine learning algorithms are able to provide more accurate and equitable results for breast cancer patients with VUS,\" said Dr. Ed Esplin M.D., Ph.D., FACMG, Clinical Geneticist at Invitae and co-author of the study. \"These definitive results can help improve outcomes for these patients and is just one example of the incredible power of coupling AI with Invitae's vast, unparalleled genetic data to further increase and accelerate the patient benefits of genetic testing.\"\nResults offer reassurance that variants of uncertain significance in genetic testing results among breast cancer patients do not lead to overuse of breast surgeries, like mastectomies. \nGenetic testing for hereditary disease, which looks at genes that can directly inform surgical, medical and surveillance strategies for breast cancer risk-reduction and treatment, has become the standard of care for assessing hereditary cancer predisposition. Although this testing can lead to high rates of uncertain results, it has been unclear if these results impact clinical management.\nConflicting results have been reported regarding whether patients with VUS are more likely to undergo breast surgeries, compared to those with negative results. This study titled, \"Real-World Breast Surgery Utilization among Breast Cancer Patients with Germline Variants of Uncertain Significance,\" examines breast surgery uptake in a large, recent sample of breast cancer patients undergoing genetic testing.\nThe study found, through a sample of more than 9,000 breast cancer patients, those with VUS results did not undergo surgical procedures more frequently than patients with negative results. These results offer reassurance that VUS results do not lead to overuse of mastectomies for breast cancer patients.\n\"Over the years there have been many discussions around preventative mastectomies and whether or not these measures have been overused in practice due to genetic testing results,\" said Dr. Kevin Hughes, Director of Cancer Genetics in the Medical University of South Carolina Department of Surgery and an author of the study. \"When we found that the uptake of breast surgeries, particularly bilateral mastectomies, was comparable between patients with negative and VUS results in this large national cohort of patients with breast cancer, it confirmed our hypothesis that receipt of a VUS does not impact clinical management.\"\nFor more information about genetic testing, visit Invitae.\nAbout Invitae Invitae (OTC: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.\nTo learn more, visit invitae.com and follow for updates on LinkedIn, X, Instagram, and Facebook @Invitae.\nSafe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's research and study findings and the company's beliefs regarding the impact of such findings. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties regarding the company's ability to successfully consummate and complete a plan of reorganization under Chapter 11; the company's ability to continue operating in the ordinary course while the Chapter 11 cases are pending; potential adverse effects of the Chapter 11 cases on the company's business, financial condition, liquidity and results of operations; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; risks associated with litigation; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.\nContact: Renee Kelley [email protected] \n View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-unveils-new-research-for-breast-cancer-patients-with-variants-of-uncertain-significance-302114308.html\nSOURCE Invitae Corporation","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426261098"}